Hjem › Immunforsvar og lidelser › Massachusetts › Boston
Kliniske studier for Immunforsvar og lidelser i Boston, MA
10 studier for Immunforsvar og lidelser søker deltakere på steder i og rundt Boston (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RekruttererFase 1
- Beth Israel Deaconess Medical Center - Research, Boston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruttererFase 3
- Massachusetts General Hospital, Boston
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
RekruttererObservasjonsstudie
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RekruttererFase 2
- Dana-Farber Cancer Institute, Boston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruttererFase 3
- Massachusetts General Hospital, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
RekruttererFase 1
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RekruttererFase 1/2
- Massachusetts General Hospital, Boston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RekruttererFase 1/2
- Brigham and Women's Hospital, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RekruttererFase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
RekruttererFase 2
- Dana-Farber Cancer Institute, Boston
Immunforsvar og lidelser-studier i andre byer
- Washington, DC13 studier
- New York City, NY12 studier
- Philadelphia, PA10 studier
- Portland, OR9 studier
- Atlanta, GA9 studier
- Houston, TX9 studier
- Chicago, IL8 studier
- Los Angeles, CA8 studier
- Cleveland, OH8 studier
- Seattle, WA6 studier
- Milwaukee, WI6 studier
- Cedar Rapids, IA6 studier
Andre studier i Boston
- Brystkreft111 studier
- Ikke-småcellet lungekreft90 studier
- Kreft (alle typer)86 studier
- Kolorektal kreft63 studier
- Metastatisk kreft63 studier
- Lungekreft62 studier
- Eggstokkreft61 studier
- Prostatakreft59 studier
- Depresjon52 studier
- Endometriekreft50 studier
- Hjertesvikt44 studier
- Akut myelogen leukemi44 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.